Innovative Bispecific Nanobody Targeting CCR7 and CD3 Complex for Addressing Chronic Lymphocytic Leukemia

VHH-P276 is a cutting-edge humanized nanobody-based therapeutic designed to target C-C motif chemokine receptor 7 (CCR7) and CD3 Complex (T Cell Receptor Complex). Currently in Biological Testing, VHH-P276 holds significant promise as a treatment for Chronic Lymphocytic Leukemia (CLL). By selectively engaging these key molecular targets, VHH-P276 aims to harness immune system modulation for effective intervention in CLL pathogenesis. The design of this bispecific antibody fusion allows for precise immune redirection, potentially improving selectivity and efficacy over conventional approaches. This innovative therapeutic candidate stands as a notable advance in the pursuit of next-generation biologics for hematological malignancies.

Licensing Opportunity

VHH-P276 is available for out-licensing and strategic collaborations. We welcome inquiries from partners seeking innovative solutions for hematological malignancies. Explore this opportunity to advance your immuno-oncology portfolio with a next-generation bispecific nanobody therapeutic.

Development Phase

Modality

VHH-P276 is a bispecific antibody fusion construct engineered by combining an antigen-binding fragment targeting CD3 and a single-domain antibody specific for human CCR7, both fused to a human IgG Fc domain. The construct is expressed in human embryonic kidney cells and produced using knobs-into-holes technology, enabling proper heavy chain pairing. As a nanobody-based molecule, VHH-P276 leverages the unique properties of single-domain antibodies, including smaller molecular size and enhanced tissue penetration, which may translate to improved targeting of infiltrative malignant cells in chronic lymphocytic leukemia. The modular fusion design provides structural stability and controlled immune activation, supporting both safety and therapeutic precision in hematologic cancer settings.

Target

CCR7 and CD3 Complex are critical molecular targets in hematological oncology. CCR7 is a G protein-coupled receptor predominantly found on lymphocytes and certain malignant B cells, where it mediates cell migration and homing. CD3 Complex constitutes a core component of the T cell receptor complex, essential for T cell activation and signal transduction. Both CCR7 and CD3 Complex are abundantly expressed in immune cell populations relevant to chronic lymphocytic leukemia. Aberrant CCR7 signaling assists in cancer cell trafficking and microenvironmental survival cues, while the CD3 Complex facilitates T cell-mediated cytotoxicity. VHH-P276 strategically targets CCR7 and CD3 Complex to bridge T cells with malignant cells, promoting immunological eradication. Dual engagement of CCR7 and CD3 Complex presents a powerful approach for immune-based clearance of leukemia cells, positioning VHH-P276 as a valuable asset in the oncology pipeline.

Mechanism of Action

VHH-P276 functions as a T cell engager by simultaneously binding CCR7 on target cells and CD3 Complex on T lymphocytes. This bispecific interaction enables close proximity between T cells and malignant cells, leading to selective immune synapse formation and T cell activation. The engagement of the CD3 Complex triggers T cell signal transduction pathways that result in cytotoxic activity against CCR7-positive leukemia cells. Moreover, modulation of CCR7 signaling may disrupt cancer cell migration and niche retention. The nanobody platform underlying VHH-P276 offers flexibility for adaptation into advanced modalities, such as antibody-drug conjugates (ADCs) or further multivalent constructs, expanding its therapeutic versatility within immune-oncology.

Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in many regions, characterized by the progressive accumulation of functionally incompetent B lymphocytes in blood, bone marrow, and lymphoid tissues. CLL affects mainly the elderly and progresses with variable clinical outcomes, from indolent courses to aggressive disease requiring intervention. Standard therapies include chemotherapy, monoclonal antibodies, and targeted agents directed at key signaling pathways. While recent advances have improved patient prognosis, limitations remain, including drug resistance, adverse effects, and relapse. There remains an unmet need for therapies that are more selective, durable, and capable of overcoming immune evasion. VHH-P276’s mechanism of redirecting T cell cytotoxicity toward malignant cells via dual CCR7 and CD3 targeting introduces a new paradigm for CLL therapy, with the potential to address therapeutic gaps and improve disease control.